Clinical trial · Observational
Radiotherapy for NSCLC to a Individualized MLD
Radiotherapy for Stage I-III Non-small Cell Lung Cancer to an Individualized MLD
NCT00573040CI-TRIAL-00003692BRONC MLDcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Our group has shown in a modeling study that increasing the radiation dose to pre-specified normal tissue dose constrains could lead to increased TCP with the same NTCP. In a subsequent phase I trial, the investigators showed the safety of this approach. Here, the investigators want to investigate its efficacy in a prospective study in patients with stage I-III NSCLC, who are selected for radical radiotherapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- 1
- description
- Inclusion criteria * Histological or cytological proven NSCLC * UICC stage I-III * Performance status 0-2 * FeV1 and DLCO at least 30% of age-predicted value Exclusion criteria: * Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma) * Stage IV * Performance status 3 or more * FeV 1 or DLCO \< 30% of the age-predicted value
Primary outcomes (1)
- measure
- death
- timeFrame
- 2,3 and 5 years
Secondary outcomes (1)
- measure
- -progression-free interval -Dyspnea (CTCAE 3.0) -Dysphagia (CTCAE 3.0) -Patterns of recurrence
- timeFrame
- 2,3 and 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological or cytological proven NSCLC * UICC stage I-III * Performance status 0-2 * FeV 1 and DLCO at least 30% of the age-predicted value Exclusion Criteria: * Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma) * UICC stage IV * Performance status 3 or more * FeV 1 and DLCO \< 30% of the age-predicted value
References
Publications (2)
- DERIVEDNalbantov G, Kietselaer B, Vandecasteele K, Oberije C, Berbee M, Troost E, Dingemans AM, van Baardwijk A, Smits K, Dekker A, Bussink J, De Ruysscher D, Lievens Y, Lambin P. Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients. Radiother Oncol. 2013 Oct;109(1):100-6. doi: 10.1016/j.radonc.2013.08.035. Epub 2013 Sep 14. PMID 24044794
- DERIVEDDehing-Oberije C, Aerts H, Yu S, De Ruysscher D, Menheere P, Hilvo M, van der Weide H, Rao B, Lambin P. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):360-8. doi: 10.1016/j.ijrobp.2010.06.011. Epub 2010 Oct 1. PMID 20888135